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TOWARDS PERSONALIZED CAUSAL INFERENCE OF
MEDICATION RESPONSE IN MOBILE HEALTH: AN
INSTRUMENTAL VARIABLE APPROACH FOR
RANDOMIZED TRIALS WITH IMPERFECT
COMPLIANCE
By Elias Chaibub Neto1, Ross L Prentice2, Brian M Bot1, Mike
Kellen1, Stephen H Friend1, Andrew D Trister1, Larsson
Omberg1, Lara Mangravite1
Mobile health studies can leverage longitudinal sensor data from
smartphones to guide the application of personalized medical inter-
ventions. In this paper, we propose that adoption of an instrumen-
tal variable approach for randomized trials with imperfect compli-
ance provides a natural framework for personalized causal inference
of medication response in mobile health studies. Randomized treat-
ment suggestions can be easily delivered to the study participants
via electronic messages popping up on the smart-phone screen. Un-
der quite general assumptions we can identify the causal effect of the
actual treatment on the response in the presence of unobserved con-
founders. We implement a personalized randomization test of the null
hypothesis of no causal effect of treatment on response, and evaluate
its performance in a large scale simulation study encompassing data
generated from linear and non-linear time series models under several
simulation conditions. In particular, we evaluate the empirical power
of the proposed test under varying degrees of compliance between the
suggested and actual treatment adopted by the participant. Our in-
vestigations provide encouraging results in terms of power and control
of type I error rates. Finally, we compare the proposed instrumental
variable approach to a simple intent-to-treat strategy, and develop
randomization confidence intervals for the causal effects.
1. Introduction. Mobile health platforms are becoming a popular tool
for the implementation of precision medicine programs. The goal is to lever-
age longitudinal sensor data, collected by smart-phones or activity tracking
devices, to better inform the application of personalized medical interven-
tions. In particular, this approach can allow the evaluation of treatment
efficacy for an individual participant, as opposed to the traditional modus
operandi of medicine, where the efficacy of a treatment is evaluated in a
clinical trial performed over an specific cohort of patients and, hence, can
only establish treatment efficacy at a population level (Topol 2012, Schork
∗1Sage Bionetworks. 2Fred Hutchinson Cancer Research Center and University of Wash-
ington, Seattle
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2015).
The personalized medicine application motivating the present work comes
from the mPower study (Trister et al 2016, Bot et al 2016), one of the studies
launched with Apple’s ResearchKit mobile platform (Friend 2015). In this
purely observational study, a participant is asked to perform activity tasks,
including tapping, voice, memory, posture and gait tests. Raw sensor data
collected from each test is processed into activity specific features, which
represent objective measures of the current state of the patient’s disease.
For instance, the number of times a participant can tap the screen of a
smartphone over a period of 20 seconds represents one such feature, where
lower number of taps indicate a more severe state. Since the activity tests
are performed by the patient on a daily basis, before and after medication,
over several months, the processed data corresponds to time series of feature
measurements annotated according to whether the measurement was taken
before or after the patient has taken medication. Supplementary Figure S1
shows an example.
This personalized medicine problem is clinically relevant since the deter-
mination of whether or not a Parkinson patient is responding to its current
medication can help the physician make more informed treatment recom-
mendations for the patient. But since mPower is an observational study, it
is challenging to draw any causal conclusions about medication effect due
to the potential of unobserved confounders.
The inference of causal effects at the personalized level is especially vul-
nerable to cyclical confounding effects, defined as any recurrent patterns or
fluctuations in the response variable that are not caused by the treatment
(Beasley et al 1997). The standard remedy to deal with such confounding
issues is to randomize the treatment schedule, which in the personalized
context (where a single participant is followed over time) boils down to ran-
domly assigning the treatments over time. In other words, the experimental
units correspond to the same study participant at different points in time.
However, it would be naive to expect a study participant to faithfully follow
an assigned treatment schedule. In order to address this problem, in this
paper we propose and evaluate the statistical properties of an instrumen-
tal variable approach (Angrist and Krueger 2001, Greenland 2000, Didelez
et al 2010, Baiocchi et al 2014) for longitudinally randomized trials with
imperfect compliance.
In the context of our motivating problem, an instrumental variable (IV)
corresponds to a randomized treatment suggestion, prompting the partic-
ipant to perform the activity task either before or after taking the medi-
cation. Such, randomized treatment suggestions can be easily delivered to
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the study participants via electronic messages displayed on the smart-phone
screen. Section 3 presents our proposed IV approach, with detailed descrip-
tions of the assumptions required for the identification of the causal effect
in our motivating application.
In order to test the null hypothesis of no causal effect between treatment
and response, we propose a randomization test (Section 3.1) and evaluate
its performance in a large scale simulation study (Section 4). We also, point
out that while the randomization test based on the IV estimator statistic is
exactly equivalent to a randomization test based on a simple intention-to-
treat statistic (Fisher et al 1990) (Section 5), it turns out that, in the context
of our motivating mobile health application, the estimates from the intent-
to-treat analysis tend to be biased towards zero, so that the causal effect
estimates generated by the IV approach might outperform the intention-
to-treat estimates, in data sets where the treatment effect is different from
zero. This observation suggests that, in practice, the IV approach might be
more appealing, especially in face of the current trend in the biomedical
field where researchers are encouraged to report parameter estimates and
confidence intervals, in addition to p-values. To meet this need, we also
develop randomization confidence intervals for the causal effects by inverting
randomization tests (Section 6). Finally, in Section 7 we discuss our results.
The next section presents general definitions, notation, and background
material on causal inference and instrumental variables.
2. Background.
2.1. General definitions and notation. Throughout this paper, we con-
sider longitudinal data indexed by t = 1, . . . , n, where Zt represents a binary
instrumental variable assuming the value 1 if the electronic suggestion asks
the participant to perform the activity task after taking medication, and
0 if it asks the participant to perform the activity task before medication
(the treatment assignment mechanism corresponds to a Bernoulli trial with
probability of success equal to P (Zt = 1) = 0.5); Xt is a binary treatment
variable set to 1 if the participant actually performs the activity task after
taking medication, and to 0 if the participant performs the activity task
before taking medication (i.e., Xt = 1 if the participant is medicated, and
Xt = 0 if he/she is unmedicated); and Yt represents a real valued response
variable representing an extracted feature from the raw activity task data
(e.g., number of taps in a fixed time interval). We represent the set of ob-
served confounders of Xt and Yt by W t. We denote by U t the set of time
specific unmeasured confounders affecting both Xt and Yt. The set of ubiq-
uitous latent variables, which influence the Yt measurements across all time
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points, is denoted by L. Similarly, we let H represent the set of ubiquitous
latent variables influencing the Xt measurements. Finally, we denote the set
of ubiquitous confounders of Xt and Yt by C. We adopt a direct acyclic
graph (DAG) representation of the dynamic causal process underlying the
observed and unobserved variables. We reserve the symbols E(), Var(), Cov()
and Cor() for the expectation, variance, covariance and correlation opera-
tors, respectively. Statistical independence and dependence are represented,
respectively, by the symbols ⊥⊥ and 6⊥⊥, while conditional independence re-
lations are described by the notation A1 ⊥⊥ A2 | A3 meaning that the set
of variables A1 is independent of the set A2 conditional on the set A3. The
set difference between sets A1 and A2 is expressed as A1 \A2. We let 1 {A}
represent the indicator function assuming value 1 if event A occurs, and 0
otherwise.
2.2. Stationary time series. In time series analysis, the concept of sta-
tionarity captures the notion of regularity over time in the probabilistic
behavior of the series (Shumway and Stoffer 2011). A strictly stationary
time series is defined as one for which the probabilistic behavior of every
collection of variables, {Y1, Y2, . . . , Yk}, is identical to the shifted collection,
{Y1+j , Y2+j , . . . , Yk+j}, for all k = 1, 2, . . ., all time points 1, . . . , k, and all
shifts j = 0,±1,±2, . . .. A milder version of stationarity (more often as-
sumed in practice) only imposes restrictions in the first two moments of the
series, that is, the mean value of the series is constant and independent of t,
and the autocovariance is a function of the shift j and not of time directly.
The stationarity assumption plays a critical role in the analysis of time
series data, since we do not typically have an independent and identically
distributed sample, {Yt,1, Yt,2, . . ., Yt,nt}, of the variable Yt, but rather a
single observation at each data point Yt. In this situation, with a single real-
ization per time point, the assumption of stationarity allows us to compute
standard sample statistics using the time series data (Shumway and Stoffer
2011). For instance, we can compute the mean value of the time series using
n−1
∑n
t=1 yt.
2.3. Causal inference. Following Pearl (2000), we adopt a mechanism-
based account of causation. In this framework, the statistical information
about a set of variables, encoded by the joint probability distribution, is
supplemented by a causal DAG encoding a qualitative description of our as-
sumptions about the causal relation between the variables. The joint prob-
ability distribution factorizes according to the causal DAG structure,
(1) P
(
x1, . . . , xp
)
=
∏
j
P
(
xj | pa(xj)
)
,
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where each element, P
(
xj | pa(xj)
)
, represents an autonomous mechanism
describing the relationship between variable Xj and its parents. A non-
parametric representation of these elements is given by xj = hj(pa(xj), ǫj),
where hj represents a deterministic function of the parents of Xj and a
random disturbance term ǫj. In this framework, causation means predicting
the consequences of an intervention over a set of variables in the DAG, where
intervention is expressed as a “surgery” on the equations and associated
causal graph.
We use the do operator notation to distinguish P
(
y | do(X = x)) from
P (y | X = x), where the former quantity describes the post-intervention
distribution of a variable Y given that the value of X was set be x by an
external intervention, while the latter represents the usual conditional dis-
tribution of Y given that we observed the value of X to be equal to x (and
is denoted the observational or pre-intervention distribution). For interven-
tions over a single variable, the relationship between the pre-intervention
and post-intervention distributions is given by the truncated factorization
formula,
(2) P
(
x1, . . . , xp | do(Xk = x′k)
)
=
∏
j 6=k
P
(
xj | pa(xj)
)
1 {xk = x′k} ,
where the removal of the equation P
(
xk | pa(xk)
)
from the product in equa-
tion (2), and the replacement of xk by x
′
k in all elements P
(
xj | pa(xj)
)
for
which Xk is a parent of Xj , formalizes what is meant by an “intervention
surgery”.
The causal effect of intervention X on the Y is usually defined as a func-
tion of the post-intervention distribution P
(
y | do(X = x)). In this paper
we adopt the average causal effect of X on Y defined as,
(3) ACE(X → Y ) = E(Y | do(X = x2))− E(Y | do(X = x1)) ,
where x1 is usually some baseline value. We say that a causal effect of X on
Y is identifiable if the post-intervention distribution P
(
y | do(X = x)), and
hence the ACE(X → Y ) quantity, is a function of observed variables only.
2.4. Instrumental variables. When it is not possible to rule out the ex-
istence of unmeasured confounders affecting both treatment and response
variables, it is still possible to use an instrumental variable to identify the
causal effect of the treatment on the response, whenever certain paramet-
ric and distributional assumptions hold. The DAG in Figure 1a provides a
graphical representation of three necessary (although not sufficient) assump-
tions (Didelez et al 2010) for the identification of the causal effect β, namely:
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(i) Zt is marginally independent of all unmeasured confounders which influ-
ence both treatment and response variables, that is Zt ⊥⊥ U t; (ii) Zt must
be statistically associated with Xt, that is Zt 6⊥⊥ Xt; and (iii) any association
between Zt and Yt must be exclusively mediated by Xt, that is, conditionally
on Xt and U t, Zt and Yt must be independent, Zt ⊥⊥ Yt | {Xt,U t}.
(a) Ut
}}⑤⑤
⑤⑤
⑤
  ❇
❇❇
❇❇
(b) U t
}}⑤⑤
⑤⑤
⑤
  ❇
❇❇
❇❇
/. -,() *+Zt // . -,() *+Xt β // . -,() *+Yt /. -,() *+Zt //
τ
::. -,() *+Xt
β // . -,() *+Yt
Fig 1. In panel a, Zt can potentially qualify as an instrumental variable for the identi-
fication of the causal effect β, since: (i) Zt is marginally independent of U t, as readily
seem by application of the d-separation criterion to the DAG structure; (ii) there is an
arrow from Zt to Xt; and (iii) there is no direct arrow from Zt to Yt, and the the indirect
causal effect of Zt on Yt is mediated exclusively by Xt. In panel b Zt does not qualify as
an instrument for the identification of β because assumption iii is violated.
3. Instrumental variables for longitudinal randomized trials with
imperfect compliance in the context of mobile health. In observa-
tional studies, assumptions i to iii need to be carefully evaluated in order
to assess the validity of the putative instrument. However, in the context of
randomized clinical trials with imperfect compliance in mobile health, as-
sumption i is valid by construction due to the randomization of the assigned
suggestions, which effectively makes variable Zt statistically independent of
any measured or unmeasured confounder of the treatment/outcome rela-
tion at time t. Assumption ii is valid if there is some degree of compliance
between the randomly assigned treatment suggestions and the treatment
effectively adopted by the study participants. (In practice, assumption ii
is likely to hold since the treatment suggestion does not seem to increase
the amount of burden to the study participant.) Assumption iii, also known
as the exclusion restriction, is only guaranteed to hold in double-blinded
trials (Hernan and Robins 2006). In the context of our motivating appli-
cation, this assumption is not guaranteed to hold, since a reminder might
change the participant behavior in other ways that affect the outcome other
than through the treatment (for instance, condition iii would be violated if
the receipt of a reminder prompted a participant to take a co-medication
other than the one under study). In any case, assumption iii seems to be
at least approximately reasonable in the proposed application. (Although in
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the particular case that a participant takes medication only once per day
and around the same time every day, it is possible that this condition might
be violated, as described in Appendix A. Nevertheless, Appendix A also
describes a strategy for minimizing this potential source of bias.)
In the following we show that the identification of the causal effect (from
observed data) holds quite generally in the context of linear and non-linear
time series models, under the additional assumptions thatXt is linearly asso-
ciated with Yt, the causal effect β is constant over time, and that the Yt and
Xt time series are stationary. Note that we only require a linear association
between Yt andXt, without making any assumptions about the relationships
between Yt and all other measured covariates, unmeasured confounders, and
lagged response variables, or about the serial dependency structure over the
Xt measurements, or about the relationship between Zt and Xt and between
Zt and Yt.
To fix ideas, consider the complex dynamic model presented in Figure 2,
which will be used as a concrete example in the following argument. Under
the assumption that Yt and Xt are linearly associated and β is constant over
time, a general time series model is given by,
(4) Yt = β Xt + f(pa(Yt) \Xt) ,
where the pa(Yt) represents the set of parents of variable Yt, and f() repre-
sents a general function of the variables in pa(Yt) \ Xt. In principle, the
variables in pa(Yt) \ Xt might include: time specific observed covariates
and unobserved confounders up to time point t (e.g., W t,W t−1, . . ., and
U t,U t−1, . . .); unobserved variables (e.g., L and C); lagged treatment and
response variables up to time point t−1 (e.g., Xt−1,Xt−2, . . . and Yt−1, Yt−2,
. . .); lagged error terms up to time point t (e.g., ǫt, ǫt−1, . . .). For the par-
ticular example in Figure 2 we have that pa(Yt) \ Xt = {W t,U t,L,C,
Xt−1, Yt−1, Yt−2, ǫt, ǫt−1, ǫt−2}.
Because in our mobile health application the instrumental variable Zt is
randomized, we have, by construction, that Zt is independent of all variables
in the set pa(Yt) \ Xt, and hence independent of any function f() of the
variables in pa(Yt) \Xt. Therefore, it follows that,
Cov(Zt, Yt) = βCov(Zt,Xt) + Cov(Zt, f(pa(Yt) \Xt))(5)
= βCov(Zt,Xt) ,
so that we can identify the causal effect,
(6) β =
Cov(Zt, Yt)
Cov(Zt,Xt)
, for all t = 1, . . . , n,
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Fig 2. DAG representation of a complex dynamic model. The response variable, Yt, follows
an autoregressive and moving average process of order 2 (i.e., is influenced by Yt−1 and
Yt−2, on the autoregressive component, and by ǫt−1 and ǫt−2 in the moving average part),
and is further influenced by observed covariates (W t, Xt, Xt−1) and unobserved variables
(U t, L, C). The treatment variable, Xt, follows an autoregressive process of order 2 (i.e.,
is influenced by Xt−1 and Xt−2, and is also influence by observed covariates (W t), and
unobserved variables (U t, H, C), in addition to the instrument, Zt.
from observed data.
Hence, for any time series model which can be represented by equation
(4) we have that, for any time point t, the causal effect of Xt on Yt can be
estimated as the ratio of the covariance estimates. The problem, however,
is that we have a single measurement for Yt, Xt and Zt per time point t,
and not a sample {(Zt,1,Xt,1, Yt,1), . . . , (Zt,nt ,Xt,nt , Yt,nt)} of measurements
of (Zt,Xt, Yt). Furthermore, both Xt and Yt time series might show serial
dependencies. Nonetheless, if the time series over the Yt and Xt variables
are stationary (so that the statistical properties of Yt, Xt and Zt variables
are similar across all t indexes), then we can estimate the (constant) causal
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effect in equation (6) using the data from all time points via the standard
sample covariance estimator,
βˆIV =
Ĉov(Zt, Yt)
Ĉov(Zt,Xt)
(7) =
n−1
∑n
t=1 ZtYt − (n−1
∑n
t=1 Zt)(n
−1∑n
t=1 Yt)
n−1
∑n
t=1 ZtXt − (n−1
∑n
t=1 Zt)(n
−1
∑n
t=1Xt)
.
At this point one might indicate that the above estimator (7) is only
valid under the assumptions that Zt is linearly associated with Xt and Yt,
since the covariance operator only captures linear associations between two
variables, and it is possible that two variables have zero covariance when the
first variable has a causal influence on a second one mediated by a non-linear
mechanism (so that the covariance operator fails to capture the non-linear
association pattern between the variables). We point out, however, that this
potential issue cannot happen in our motivating application since both Zt
and Xt are binary variables, and it can be shown (see Appendix B) that an
estimate of the non-parametric average causal effect of Zt on Yt,
ÂCE(Zt → Yt) = Ê
(
Yt | do(Zt = 1)
)− Ê(Yt | do(Zt = 0))
(8) =
n−1
∑n
t=1 ZtYt − (n−1
∑n
t=1 Zt)(n
−1∑n
t=1 Yt)
(n−1
∑n
t=1 Zt)(1− n−1
∑n
t=1 Zt)
is proportional to Ĉov(Zt, Yt), and that an estimate of the non-parametric
causal effect of Zt on Xt,
ÂCE(Zt → Xt) = Ê
(
Xt | do(Zt = 1)
)− Ê(Xt | do(Zt = 0))
(9) =
n−1
∑n
t=1 ZtXt − (n−1
∑n
t=1 Zt)(n
−1∑n
t=1Xt)
(n−1
∑n
t=1 Zt)(1− n−1
∑n
t=1 Zt)
is proportional to Ĉov(Zt,Xt), and that the estimator in (7) actually corre-
sponds to the ratio of the non-parametric causal effects in (8) and (9), show-
ing that the estimator in (7) is still valid without the linearity assumptions
(although its validity still requires additivity in the errors and unmeasured
confounders).
In addition to confounding, selection bias is another major obstacle to
the validity of causal inference in clinical studies. Appendix C presents a
discussion of selection bias in the context of personalized mobile health and
shows examples where selection mechanisms can lead to bias in the medica-
tion effect estimates (as well as, situations where selection does not bias the
IV estimates).
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3.1. Randomization test. We implemented a randomization test (Ernst
2004) for testing the sharp null hypothesis, H0 : β = 0, against the al-
ternative H1 : β 6= 0. The randomization null distribution is generated by
evaluating the statistic βˆIV in (7) on a large number of shuffled versions of
the data, where the Yt measurements are shuffled relative to the (Zt,Xt)
measurements (whose connection is kept intact in order to preserve the as-
sociation between the Zt and Xt variables).
4. Simulation study. In order to evaluate the statistical properties
of the proposed randomization test, we performed a large scale simulation
study comprised of 80 separate simulation experiments involving 10 distinct
linear and non-linear time series models described in Table 1, and 8 distinct
simulation settings described in Table 2.
Table 1
Time series models used in the simulation study.
name response model
ARMA(1, 1) Yt = g + φ1 Yt−1 + θ1 ǫt−1 + ǫt
ARMA(1, 0) Yt = g + φ1 Yt−1 + ǫt
ARMA(0, 1) Yt = g + θ1 ǫt−1 + ǫt
ARMA(0, 0) Yt = g + ǫt
ARCH(1) Yt = g + ǫt σt , σ
2
t = µσ + a1 Y
2
t−1
GARCH(1, 1) Yt = g + ǫt σt , σ
2
t = µσ + a1 Y
2
t−1 + b1σ
2
t−1
TAR(1) Yt = g + φ1,1 Yt−11 {Tt ≤ 0}+ φ1,2 Yt−11 {Tt > 0}+ ǫt
LSTAR(1) Yt = g + φ1,1 Yt−1G(Tt) + φ1,2 Yt−1(1−G(Tt)) + ǫt
G(tt) = 1/(1 + e
−tt)
ESTAR(1) Yt = g + φ1,1 Yt−1G(Tt) + φ1,2 Yt−1(1−G(Tt)) + ǫt
G(tt) = 1− e−t2t
SETAR(1) Yt = g + φ1,1 Yt−11 {Yt−1 ≤ 0}+ φ1,2 Yt−11 {Yt−1 > 0}+ ǫt
where g = λWt + η Ut + ψ L+ β Xt + δ1Xt−1
Table 2
Distinct settings used in the simulation study.
setting error type data simulated under dependency for Xt
1: N(0, 1) H1 : β 6= 0 complex
2: U(−√3,√3) H1 : β 6= 0 complex
3: N(0, 1) H0 : β = 0 complex
4: U(−√3,√3) H0 : β = 0 complex
5: N(0, 1) H1 : β 6= 0 simple
6: U(−√3,√3) H1 : β 6= 0 simple
7: N(0, 1) H0 : β = 0 simple
8: U(−√3,√3) H0 : β = 0 simple
The time series models included: autoregressive moving average (ARMA)
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models (Box et al 1994); autoregressive conditional heteroskedasticity (ARCH)
models (Engle 1982); generalized autoregressive conditional heteroskedas-
ticity (GARCH) models (Bollerslev 1986); threshold autoregressive (TAR)
models (Tong 1978); self exciting threshold autoregressive (SETAR) models
(Tong and Lim 1980); and logistic and exponential smooth transition au-
toregressive (LSTAR and STAR) models (Van Dijk 2002). The 8 distinct
simulation settings in Table 2 comprise all possible combinations of simula-
tions generated: under the null or alternative hypothesis; using gaussian or
uniform error terms in the generation of the continuous variables, ǫt, Ut,Wt,
L, and H; and adopting either a complex or a simple dependency structure
for the Xt variables. For the complex dependency structure, the Xt variables
were simulated according to,
(10) Xt = 1 {αZt + ωWt + γ Ut + ϕH + ε∗t > 0} ,
with the error term ε∗t−1 generated according to the AR(1) process,
(11) ε∗t = ρ ε
∗
t−1 + εt , εt ∼ N(0, 1) or εt ∼ U(−
√
3,
√
3) ,
whereas for the simple dependency structure,
(12) Xt = 1 {αZt + ωWt + γ Ut + εt > 0} .
Note that under the complex dependency structure the Xt measurements
are dependent due to the effect of the common latent variable H and to
the serial association induced by the AR(1) process underlying the ε∗t error
terms. Under the simple dependency structure, on the other hand, the Xt
measurements are independent. Observe, as well, that in the simulations
employing uniform distributions, we adopted the range [−√3,√3] in order
to ensure that the variance is still 1. For the TAR, LSTAR, and ESTAR
models, we generated the threshold variable, Tt, from a standard normal
distribution.
Each one of the 80 distinct simulation experiments were based on 10,000
simulated data sets. Each simulated data set was generated using a unique
combination of simulation parameter values. Table 3 presents the ranges
of the simulation parameter values employed in the study. We selected a
wide range, [−4, 4], for model parameters β, ω, γ, ϕ, λ, η, ψ, δ1, θ1. The
range of α was strictly positive since this parameter controls the amount of
compliance between Zt and Xt, which is assumed to be positive. The range
for parameters φ1, φ1,1, φ1,2, ρ was set to [−0.8, 0.8], since these parameters
control autoregressive processes of order 1, and need to be constrained be-
tween [−1, 1] in order to ensure the stationarity of the time series. The
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parameter a1 controls the autoregressive processes over the variance terms
in a ARCH(1) or GARCH(1, 1) process and was allowed to vary between
[0, 0.99] in our simulations. For GARCH(1, 1) models the additional moving
average parameter b1 is set to 1 − a1 in order to ensure that the station-
arity condition a1 + b1 < 1 holds. The range of sample size parameter, n,
was set to realistic values we expect to see in practice. In order to select
parameter values spread as uniformly as possible over the entire parameter
range we employed a Latin hypercube design (Santner et al 2003), optimized
according to the maximin distance criterium (Johnson et al 1990), in the
determination of the parameter values used on each of the 10,000 simulated
data sets for each of the 80 simulation experiments. In total, our simulations
encompassed 800,000 simulated data sets.
Table 3
Simulation parameter ranges.
parameter range
α [0.5 , 4]
β , ω , γ , ϕ , λ , η , ψ , δ1 , θ1 [−4 , 4]
φ1 , φ1,1 , φ1,2 , ρ [−0.8 , 0.8]
a1 [0 , 0.99]
n {50, 51, 52, . . . , 800}
In order to evaluate if adjustment for observed confounders would improve
the performance of the randomization test, we compared straight causal
effect estimates against adjusted estimates, where theXt and Yt variables are
replaced by the residuals of the regressions of these variables on the observed
confounder Wt. Also, in order to illustrate the importance of employing the
instrumental variable approach in the presence of unobserved confounders,
we compare the straight and adjusted IV approaches against naive tests for
the null H0 : β = 0, based on standard and adjusted t-tests (where, again,
we replace the Xt and Yt by residuals in the adjusted t-test).
Supplementary Figure S2a presents the distributions of the autocorre-
lations between Yt−1 and Yt, for all 10 models in Table 1. Supplementary
Figure S2b reports the distributions of the correlations between the instru-
mental variable and all other variables. Figure 3a presents the empirical
type I error rates, as a function of the nominal level α, for all 400,000 data
sets simulated under H0 : β = 0. The plot clearly shows that the random-
ization test for the straight and adjusted IV approaches (brown and blue
curves) is able to control the type I error rates at the nominal levels. Use
of t-tests, on the other hand, lead to highly inflated error rates, since these
naive approaches mistakenly detect the presence of a causal effect whenever
the treatment and response variables are associated entirely because of the
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influence of observed and unobserved confounders. The plot also shows that
the adjustment for the observed covariate (orange curve) is able to reduce
the type I error rate by accounting for part of the association between treat-
ment and response variables, as illustrated by the drop in error rate from
the red (un-adjusted) to the orange (adjusted) t-tests.
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Fig 3. Comparison of empirical type I error rates and empirical power.
Figure 3b presents the empirical power, as a function of α, for all 400,000
data sets simulated under H1 : β 6= 0. As expected, the dominance of the
blue curve over the brown one shows that adjustment for observed con-
founders can improve the power of the randomization test to detect a causal
effect. The plot also shows that the t-tests are better powered than the ran-
domization test to detect a causal effect when one exists. We point out,
however, that this increased power is an artifact of the biased estimates for
β delivered by the naive approaches, as clearly illustrated in Supplementary
Figure S3, where the βˆ estimates generated by the naive approaches tend to
show larger bias than the estimates generated by the instrumental variable
approach.
In order to evaluate the power of the IV approach under varying amounts
of compliance by the study participants, and under different sample sizes
and strengths of the causal effects, we present in Figure 4 (and in Supple-
mentary Figures S4 and S5) empirical power curves stratified according to
the correlation between the instrumental and treatment variables, for 4 dis-
joint sample size intervals, 50 ≤ n < 200, 200 ≤ n < 400, 400 ≤ n < 600,
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and 600 ≤ n ≤ 800, when the causal effect is weak (i.e., |β| < 1, Figure
4), moderate (i.e., 1 ≤ |β| < 3, Supplementary Figure S4), and strong (i.e.,
3 ≤ |β| ≤ 4, Supplementary Figure S5). Inspection of the three plots shows,
as one would expect, that for a fixed compliance level the power increases
with increasing sample sizes and increasing strength (in absolute value) of
the causal effects. Additionally, for any given panel the power increases as
a function of the amount of compliance.
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Fig 4. Empirical power curves for the adjusted IV causal effect estimator stratified accord-
ing to cor(X, Z) and to the sample size, n, for simulated data sets generated with weak
causal effect, |β| < 1. The vertical dotted line is set at α = 0.05.
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It is important to point out that weak compliance levels not only lead to
under-powered tests, but can also lead to highly biased estimates of causal
effect when the estimated covariance between instrumental and treatment
variables is close to zero (see Supplementary Figure S6 for an illustration).
Hence, in practice, it is necessary to check the IV assumption that the in-
strumental and treatment variables are statistically associated if the main
goal is to estimate the causal effect. We point out, however, that violations
of this assumption do not not lead to inflation of type I error rates, as il-
lustrated in Supplementary Figure S7b. Finally, we point out that violation
of stationarity does not lead to inflated type I error rates, but can wipe out
the power to detect a causal effect, as illustrated in Supplementary Figure
S8. The R code (R Core Team 2014) implementing the randomization tests
and confidence intervals, and used in the generation of the simulation results
and figures is available at: https://www.synapse.org/mhealthIV.
5. Comparison with intention-to-treat analysis. The intention-to-
treat (ITT) analysis is usually regarded as the preferred approach for the
analysis of randomized clinical trials (FDA 1998). The ITT estimator has
an interpretation as an estimator of the effect of treatment suggestion on
the response variable and, as such, is free of confounding influences. (Note,
however, that in order for the ITT effect to have a meaningful interpreta-
tion, the instrument should correspond as much as possible to the actual
intervention). In the context of our mobile health application, and assum-
ing, once again, stationarity of response data, constance of the causal effect
over time, and the core IV assumptions, we have that an unbiased estimator
for the effect of treatment assignment on the response is given by Neyman’s
average causal effect estimator,
βˆITT =
∑n
t=1 Yt 1 {Zt = 1}∑n
t=1 1 {Zt = 1}
−
∑n
t=1 Yt 1 {Zt = 0}∑n
t=1 1 {Zt = 0}
=
n−1
∑n
t=1 ZtYt − (n−1
∑n
t=1 Zt)(n
−1∑n
t=1 Yt)
n−1
∑n
t=1 Z
2
t − (n−1
∑n
t=1 Zt)
2
=
Ĉov(Zt, Yt)
V̂ar(Zt)
,(13)
which also corresponds to a simple ordinary least squares estimator.
Even though βˆITT estimates the effect of the treatment assignment on the
response, as opposed to the effect of the actual treatment received by the
participant on the response, it is well known that the ITT comparison still
provides a valid statistical test for the null hypothesis of no causal effect of
the actual treatment on the response (Rosenberger and Lachin 2002, Hernan
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and Hernandez-Diaz 2012), as long as, the same core conditions required by
the instrumental variable approach hold. (Note that while Zt ⊥⊥ U t holds
by construction, and Zt 6⊥⊥ Xt is expected to hold, the exclusion restriction,
Zt ⊥⊥ Yt | {Xt,U t}, isn’t guaranteed to hold, as discussed before.)
As a matter of fact, the randomization tests based on the IV and ITT es-
timators produce exactly the same p-value if we use the same permutations
of the response data in the construction of the randomization null distribu-
tion of both tests. Both estimators, share the same numerator, Ĉov(Zt, Yt),
which is a function of Yt and vary with each distinct permutation of the
response data employed in the generation of the randomization null distri-
bution, whereas the denominators of the IV and ITT estimators are different
(i.e., Ĉov(Zt, Yt) for the IV estimator, and V̂ar(Zt) for the ITT estimator),
but in both cases do not depend on the response data. Therefore, it follows
that βˆIV = K
−1 βˆITT where, K = ÂCE(Zt → Xt) = Ĉov(Zt,Xt)/V̂ ar(Zt),
is not a function of Yt and is constant across all permutations of the re-
sponse data used in the construction of the randomization test null distri-
bution. Figure 5 shows an illustrative example were we employed the same
permutations of the response data in the construction of the IV and ITT
null distributions.
We point out, however, that even though adoption of the IV or ITT esti-
mators leads to exactly the same randomization test p-values, the estimates
produced by both approaches are different. It is well known that if the treat-
ment has a non-null effect on the response (i.e., β 6= 0), the ITT approach
underestimates the treatment effect when participants do not fully adhere to
their assigned treatment, that is, the assigned treatment effect will be closer
to zero than the actual treatment effect due to contamination of treatment
groups caused by non-compliance. This phenomenon is known as the “bias
towards the null” in placebo-controlled double-blind randomized clinical tri-
als (Hernan and Hernandez-Diaz 2012). The upside of this phenomenon is
that, when the treatment has no effect on the response (i.e., β = 0), this
“bias towards zero” works in favor the ITT approach, which can then cor-
rectly estimate the null effect of the treatment on the response.
In the context of our mobile health application, where by construction
the treatment assignment mechanism corresponds to a Bernoulli trial with
probability of success equal to P (Zt = 1) = p = 0.5, we have that treat-
ment effects estimated by the ITT approach tend to be closer to zero than
the estimates from the IV approach since: (i) if the sample size is not too
small, the denominator of βˆITT , V̂ ar(Zt), will generally approximate the
maximum theoretical variance Var(Zt) = 0.25 (recall that the variance of a
Bernoulli random variable with probability of success, p, is given by p (1−p),
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Fig 5. Randomization null distributions based on the IV and ITT estimators, computed
using the same random permutations of the response data. In spite of the wider spread of
the IV null distribution, when compared to the ITT null, in both distributions we have that
exactly 5,013 out of the 100,000 permutations of the response data, lead to statistics equal
or larger than the observed values in the original data (βˆIV = 1.433 and βˆITT = 0.902,
shown by the blue vertical lines). Hence, the p-value derived from both randomization tests
are identical and equal to 0.05013.
and reaches the maximum of 0.25 when p = 0.5); and (ii) the denominator
of βˆIV will generally be smaller or equal than the denominator of βˆITT ,
Ĉov(Zt,Xt) ≤ V̂ ar(Zt), since Ĉov(Zt,Xt) increases with the amount of
compliance, reaching its maximum when the compliance is perfect, in which
case, Xt = Zt for all t, and Ĉov(Zt,Xt) = V̂ ar(Zt) ≈ 0.25. This “bias to-
wards zero” phenomenon is illustrated in Figure 5 by the smaller spread
around zero of the randomization null distribution based on the ITT esti-
mator, in comparison to the IV randomization null. Supplementary Figure
S9 reports a bias comparison between the IV and ITT approaches using the
data from the simulation study, and further illustrates this point.
6. Confidence intervals from randomization tests. In this section
we describe how to build confidence intervals for the causal effect, β, using
the p-values from randomization tests (Garthwaite 1996, Ernst 2004). The
procedure is straightforward but requires a considerable amount of compu-
tation (which, nonetheless, can be easily parallelized), as we need to test the
null, H0 : β = βj , for each βj on a grid of causal effect values, β1, . . . , βJ ,
and then construct an interval estimate for β by considering all βj for which
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the randomization tests did not reject the null.
Explicitly, assume for a moment that randomization tests for testing H0 :
β = βj against one-sided alternative hypothesis H1 : β < βj and H1 : β > βj
are available. Exploring the correspondence between confidence intervals
and hypothesis tests, we obtain a 100(1 − 2α)% confidence interval (CI)
for β by searching for a lower bound value, βL, such that H0 : β = βL is
rejected in favor of H1 : β > βL at a significance α, and by searching for
an upper bound value, βU , such that H0 : β = βU is rejected in favor of
H1 : β < βU at the same significance level (Garthwaite 1996). While an
efficient search procedure for finding CI bounds has been proposed in the
literature (Garthwaite 1996), the approach requires the specification of the
significant level before hand. In order to avoid this constraint, we generate
a “one-sided randomization p-value profile” (Figure 6) which can be used to
determine the 100(1− 2α)% CI for any desired α level. This p-value profile
is generated as follows: (i) compute the observed causal effect estimate,
βˆIV ; (ii) for each βj < βˆIV , in a grid of decreasing βj values, compute the
randomization p-value from the one-sided test H0 : β = βj vs H1 : β > βj ;
(iii) repeat step ii until a p-value equal to zero is reached; (iv) for each
βj > βˆIV , in a grid of increasing βj values, compute the p-value from the
one-sided test H0 : β = βj vs H1 : β < βj ; (v) repeat step iv until a
randomization p-value equal to zero is found.
By exploring the equivalence between randomization tests based on the
βˆIV and βˆITT statistics (described in the previous section), we can easily
compute the required randomization p-values using the βˆITT statistic. In
other words, instead of directly generating a randomization distribution un-
der the null hypothesis that the causal effect is equal to βj (i.e., H0 : β = βj),
we generate a randomization distribution under the equivalent null hypothe-
sis that the intention-to-treat effect is equal to βj K (i.e., H0 : ITT = βj K),
where K = Ĉov(Zt,Xt)/V̂ar(Zt) is constant across all permutations of the
response data used in the construction of the randomization null, and con-
nects the βˆIV and βˆITT statistics according to the relation βˆITT = K βˆIV .
The practical advantage of the test based on ITT effects is that it amounts
to a simple two sample location problem for testing whether the difference
in average response between the assigned treatment and assigned control
groups is equal to βj K. The implementation of randomization tests for this
two sample location problem is straightforward (Garthwaite 1996): we only
need to add βj K for each Yt data point in the assigned control group (i.e., t
for which Zt = 0), while leaving the response data from the assigned treat-
ment group (Zt = 1) unchanged, and then run a randomization test for
testing the null hypothesis that the ITT effect (in this modified version of
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Fig 6. Randomization confidence intervals for a data set simulated from an autoregressive
model. The estimated effect was βˆIV ≈ 0.54 (true causal effect was 0.5). The grey curve
represents the one-sided randomization p-value profile. The x-axis represents the causal
effects (βj) and the y-axis represents the corresponding randomization p-value for testing
the null H0 : β = βj against H1 : β > βj (for βj < βˆIV ) and H1 : β < βj (for βj > βˆIV ).
The 100(1 − 2α)% CI for any given α corresponds to interval inside the p-value profile
(along the x-axis) at an α height (along the y-axis). In this example, the 99% CI (brown)
contains 0, illustrating that we do not reject the null H0 : β = 0 at a α = 0.01 (in this
example the two tailed p-value was 0.0248). The null H0 : β = 0 is, nonetheless, rejected
at α equal to 0.05 and 0.1, since the respective 95% (blue) and 90% (green) confidence
intervals do not contain 0.
the data) is equal to zero, against the alternative one-sided hypothesis that
the ITT effect is positive (for βj < βˆIV ), and against the alternative that
the ITT effect is negative (for βj > βˆIV ).
The grey curve in Figure 6 shows the one-sided p-value profile computed
according to the algorithm described above. The x-axis reports the causal
effect values (i.e., the βj values) and the y-axis presents the corresponding
randomization p-value for testing the null H0 : β = βj against H1 : β > βj
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(for βj < βˆIV ) and H1 : β < βj (for βj > βˆIV ). The 100(1 − 2α)% CI of
any given α corresponds to interval inside the p-value profile (along the x-
axis) at an α height (along the y-axis). The 90%, 95%, and 99% confidence
intervals are shown in green, blue, and brown, respectively.
7. Discussion. In this paper we proposed the use of instrumental vari-
ables in randomized trials with imperfect compliance for causal inference
of medication response in mobile health. The present work was motivated
by a personalized medicine problem arising from the mPower study, and
represents an improvement over a previous contribution (Chaibub Neto et
al 2016b), which was based on the naive assumption of no unobserved con-
founders.
A practical objective of the present work was to evaluate the empirical
power of the randomization test, and assess the feasibility of the IV approach
in the context of mobile health. We were particularly interested in evaluating
the empirical power under varying amounts of compliance by the study
participants. Our simulations suggest that, at least for the reasonably wide
range of parameter values evaluated in this work, the IV approach is indeed
well powered, even when the degree of compliance is moderate. Additionally,
in practice, it seems reasonable to expect moderate to high compliance levels
since the simple electronic suggestion that the participant should perform
the activity task either before or after taking medication does not seem to
cause much of a burden to a participant, and we expect that the participants
will be able to comply with the suggested treatment most of the time.
As discussed in Section 5, the randomization test based on the IV esti-
mator is equivalent to the randomization test based on the ITT estimator.
Therefore, a simple ITT analysis could be used in place of the IV approach.
We point out, however, that often times a researcher will be interested in
estimating the strength of the causal effect when it turns out that a statis-
tical test suggests the effect is different from zero. In this situation, and if
data checks suggest that the core IV conditions and additional parametric
assumptions required by the IV approach seem to hold (for instance we can
empirically check whether the instrument and treatment variables are associ-
ated, whether the association between the treatment and response variables
seem to be approximately linear, whether the response and treatment data
time series seem to be stationary, and etc), then the IV estimator might
be preferred over the ITT estimator, as the latter tends to be biased to-
wards zero (Supplementary Figure S9a). Otherwise, both estimators might
be biased.
The present work relies on the mechanism-based account of causation
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championed by Pearl (2000). Application of Pearl’s interventional calculus
in the context of time series models was first proposed by Eichler and Didelez
(2007, 2010) and Eichler (2012). We point out, however, that their approach
is not based in IVs, and their goal was to model the effect of an intervention
in one component of a multivariate time series model on another component
at a later point in time.
Randomized clinical trials have been used in the evaluation of the ef-
fectiveness of mobile interventions for health behavior change or disease
management in several areas including: smoking cessation, physical activ-
ity/diet, sexual health, alcoholism, CPR interventions, medication adher-
ence, diabetes management, asthma and chronic obstructive pulmonary in-
terventions, hypertension, and psychological interventions (Free et al 2013).
These trials were, nonetheless, tailored to the conventional framework of
population medicine, in opposition to the personalized medicine focus of the
present work.
Single case research designs (Franklin et al 1997) have also been used
in the context mobile health (Dallery et al 2013). These studies generally
include a small number of participants subjected to periods of treatment
intercalated with periods of non-treatment, and the longitudinal data of
each participant is usually analyzed separately. The goal, nonetheless, is to
establish the efficacy of a treatment or intervention in a given cohort, and
not at the personalized level.
The recently proposed micro-randomization designs (Liao et al 2015,
Dempsey et al 2015) generalize single-case designs by allowing more tra-
ditional statistical analysis of multiple participants concomitantly, under a
population medicine framework. Micro-randomization designs adopt a po-
tential outcomes framework and allow the inference of proximal time depen-
dent causal effects of just-in-time mobile interventions. A goal of just-in-time
interventions is to promote behavior change, and help participants manage
stressful situations in the moment the intervention is needed (e.g., a par-
ticipant of a drinking cessation program might benefit from a motivational
message popping up on the smartphone screen when in close proximity to a
liquor store). Hence, micro-randomization trials address a different problem
from the one motivating the present work.
Although the approach proposed in this paper represents a step towards
causal inference for medication response in mobile health applications, an
important pragmatic challenge still remains. Because participants are not
blinded to the treatment they are actually receiving, it is not really possible
the tell whether an observed “medication response” is truly caused by a
medication effect, or because the participant tends to perform better after
22 CHAIBUB NETO E. ET. AL.
taking medication due to psychosomatic effects, or due to a combination
of both medication and psychosomatic effects. Hence, the unambiguous de-
termination of the medication effect is still contingent on the assumption
that the study participant is not prone to psychosomatic effects. We point
out, however, that Chaibub Neto (2016) recently proposed an instrumental
variable approach to disentangle treatment and placebo effects in unblinded
trials, which could be potentially employed in our motivating application.
Even though the personalized medicine problem motivating the present
work involves the self-selection of study participants, most of the perils and
pitfalls involved in web-based epidemiological studies and surveys (Keiding
and Louis 2016) are avoided by our focus on the estimation of participant-
specific treatment effects. Finally, it is important to point out that while
the proposed IV approach is well equipped to handle confounding, it is still
vulnerable to selection bias.
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Fig S1. Example of data collected by the mPower study. The figure shows the data from
a single study participant, collected over a six months period, and color coded according to
whether the number of taps was recorded when the participant was medicated (blue dots)
or not (red dots).
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Fig S2. Panel a presents the distribution of the (lag = 1) autocorrelations for the response
variables for all 10 models in Table 1. For the ARCH(1) and GARCH(1, 1) models the
dotted and full line curves show, respectively, the lag 1 autocorrelations for the response
and squared response measurements. We see that except for the ARMA(0, 0) model (which
does not impose a serial correlation structure over the response variable) all other models
generate autocorrelated responses. Panel b presents the distributions of the correlations be-
tween the instrumental variable, Z, and all other variables. The densities were estimated
using all 800,000 simulated data sets. The densities clearly show mostly positive correla-
tions between the instrumental and treatment variables (blue and silver curves), moderate
correlations between the instrumental and response variables (red and brown curves), and
weak correlations between the instrument and all other measured covariates and unmea-
sured confounders.
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Fig S3. Comparison of the bias of the t-tests and IV estimators. Panels a and b show
the results for data simulated under the null and alternative hypothesis, respectively. Note
that the βˆ estimates generated by the t-tests tend to show larger bias than the estimates
generated by the instrumental variable approach, as illustrated by the heavier trails of the
t-test (red) and adjusted t-test (orange) distributions, when compared to the IV approaches.
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Fig S4. Empirical power curves for the adjusted IV causal effect estimator stratified ac-
cording to cor(X, Z) and to the sample size, n, for simulated data sets generated with
moderate causal effect, 1 ≤ |β| < 3. The vertical dotted line is set at α = 0.05.
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Fig S5. Empirical power curves for the adjusted IV causal effect estimator stratified ac-
cording to cor(X, Z) and to the sample size, n, for simulated data sets generated with
strong causal effect, |β| ≥ 3. The vertical dotted line is set at α = 0.05.
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Fig S6. Panel a shows the distribution of cor(Z,X) across all simulated data sets. High-
lighted in red is the distribution of cor(Z,X) for the data sets for which the correlation
is not statistically different from zero at a significance level equal to 0.05. Panels b and
c show scatter-plots of β − βˆ against cor(Z,X) for 5,000 randomly selected data sets, for
which the correlation is not statistically different from zero (panel b), and for which the
correlation is statistically different from zero (panel c). It is clear that the IV estimator
can generate highly biased estimates when the Zt 6⊥⊥ Xt assumption is violated (note that
the x-axis range in panel b is orders of magnitude larger than in panel c).
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Fig S7. Empirical type I error rates and empirical power, when compliance is very low
(i.e., Cov(X,Z) is close to zero). Panel a shows the randomization null distribution for
one simulated data set where the causal effect estimated by the adjusted IV approach was
extremely high (βˆ = 9329.01). Even though the estimate is super inflated by the small
Ĉov(X,Z) ≈ −0.002 estimate in the denominator of βˆ, the randomization test is still
non-significant. This protection follows from the fact that we only shuffle the response
data in the generation of the randomization test null distribution, but keep the association
of the instrumental and treatment variables intact, so that the denominator of the IV
estimator is always the same in all shufflyings of the data used to generate the null. Panel
b shows the empirical type I error rates (dark green) and empirical power (dark orange) for
the simulations for which cor(X,Z) was not statistically different from zero (encompassing
22,902 data sets simulated under the null and 22,923 under the alternative hypothesis).
Note that the type I error rate is still well controlled but the test lacks power to detect
causal effects when they exist. The practical consequence of these observations is that it is
still safe to apply the randomization tests for very low levels of compliance if the goal is
simply to help a physician flag patients which respond to medication (as low compliance
will drastically reduce the statistical power but won’t lead to spurious findings).
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Fig S8. Empirical type I error rates and empirical power, under violations of the station-
arity assumption. Panel a shows that the type I error rates for the straight and adjusted
IV approaches still match the nominal levels. Panel b, on the other hand, shows that the
empirical power to detect the causal effect is completely wiped out. For these simulations
we only considered the ARMA(1, 1), ARMA(1, 0), TAR(1), and SETAR(1) models. We
set the autoregressive parameters, φ1, φ1,1, φ1,2, and ρ, to 1 in order to generate non-
stationary data while still avoiding explosive processes. For all remaining parameters, we
adopted the same parameter ranges of Table 3. As before, we generated the data under the
eight simulation settings of Table 2.
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Fig S9. Bias comparison between the IV and ITT approaches. Panel a compares the IV and
ITT approaches using data generated under the alternative hypothesis, H1 : β 6= 0. Results
show that the ITT approach tends to generate more biased estimates of β than the IV
approach, whose density puts more probability mass at values close to zero (brown density).
Panel b shows the results for data generated under the null hypothesis, H0 : β = 0, where
the ITT approach tends to generate less biased estimates of β = 0 than the IV approach.
Note that while the IV densities (brown curves) are similar in both panels (with peak close
to 0.5 at β− βˆ ≈ 0), the variation in the shape of the ITT densities (dark-green curves) is
due to the “bias towards zero” phenomenon, which works against the ITT estimator under
H1 : β 6= 0 (panel a), but on its favor under H0 : β = 0 (panel b).
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10. Appendix A: minimizing bias due to the time of the day
that the activity is performed. In the context of our motivating ap-
plication, it is the participant who decides the time of the day that he/she
will perform the activity task. Because of this particularity, it is possible
that the suggested treatment, Zt, will influence both the treatment actually
adopted by the participant, Xt, and the the time of the day that the partic-
ipant performs the task (for now on, denoted by TOD). Explicitly, suppose
that a participant takes medication regularly at about the same time every
day (say, around noon). If the randomized suggestion asks the participant to
perform the task before taking medication (i.e., Zt = 0), and the participant
decides to comply with Zt (i.e., Xt = 0), the participant will perform the task
in the morning. Similarly, if the participant complies with a suggestion to
perform the task after taking medication, then the participant will perform
the task in the afternoon. Hence, if the participant tends to comply with the
suggested treatment, we have that most tasks performed before medication
will be done in the morning, and most tasks performed after medication will
be done in the afternoon. Therefore, it is not really possible to determine
whether the medication has an effect on the outcome (task performance), or
if an association between Xt and Yt is actually caused by daily physiological
variations due to circadian rhythms (e.g., the participant might inherently
tend to do better in the afternoon than in the morning), or caused by daily
routine activities for which the TOD might be a surrogate measurement.
For instance, features extracted from accelerometer data recorded during a
walking task (where the participant is asked to put its phone in the front
pocket and walk in a straight line for a fixed period of time) are affected by
the clothing the participant is using during the activity. Hence, if the par-
ticipant tends to perform the “before medication” walking activity in the
morning, while wearing comfortable pajamas and sandals, and the “after
medication” activity later in the day, while wearing tight paints and shoes,
it is not possible to tell if the association between Xt and Yt is due to the
medication or to the clothing the participant is using.
Graphically, the causal DAG representing the influence of the TOD is
shown is Supplementary Figure S10a, where Mt represents the usual time
that the participant takes its medication and Tt represents the TOD. The
variableDXt represents the participant’s decision about the treatment he/she
will actually take (note that, in addition to the suggested treatment, Zt,
the unobserved confounder of the treatment/outcome relation, Ut, also in-
fluences the participant’s decision). The arrow from Tt to Yt indicates the
influence of circadian rhythms or daily routine activities (for which the TOD
is a surrogate variable) on the performance on the activity t
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able DTt represents the participant’s decision about what time he/she will
perform the activity task. Note that DTt is a function of D
X
t and Mt since
if a participant takes medication around the same time every day, then the
time the participant decides to performs the activity task will depend on the
treatment that the participant decided to take. The model also allows for the
presence of unmeasured confounders, Vt, influencing D
T
t and the outcome.
The arrows from DXt to Xt and from D
T
t to Tt indicate that the participant’s
decisions precedes the actual actions and that unexpected events can change
the actual treatment and the time the activity is performed.
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Fig S10. Panel a shows the causal DAG representing the influence of the treatment sug-
gestions, Zt, on the treatment adopted, Xt, on time of the day that the activity was per-
formed (TOD), Tt, and on the outcome, Yt. Please, refer to the text for a description of
the variables and explanations. Panel b shows the case where the modified suggestions, Z∗t ,
generate a narrow time window between the before and after medication activity tasks, so
that the TOD is unlikely to influence the outcome.
It is clear from Supplementary Figure S10a that even though the TOD
is not technically a confounder of the medication effect (in the sense that a
confounder of the treatment/outcome relation is usually defined as a variable
that is a common cause of Xt and Yt) failing to adjust for the influence of
the TOD in the outcome, leads to a biased estimate of the medication effect
because the core instrumental variable assumption iii, Zt ⊥⊥ Yt | {Xt, Ut},
is violated due to the additional path Zt → DXt → DTt → Tt → Yt mediated
by the TOD.
In applications based on fast acting drugs (such was L-dopa used in treat-
ing Parkinson’s disease, which usually produces an effect is less than an
hour), a simple solution to decrease the potential influence of the TOD is to
slightly modify the Zt suggestions. Instead of simply asking the participant
to perform the activity task either before or after taking medication, we
could ask the participants to perform the “before medication” task just be-
fore taking the medication, and the “after medication” task at a fixed period
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Fig S11. Influence of the time the participant usually takes its medication on the ran-
domization of the treatments across the time of the day. In all three panels the modified
treatment suggestions (“please, perform the activity task right before taking your medica-
tion” and “please, perform the activity task about one hour after taking your medication”)
are randomized across the days (and the participant fully complies with the suggestions).
Panel a shows an example where the participant takes medication once per day at noon.
All the tasks performed before medication are done a little earlier than noon, while all
tasks performed after medication are done at 1pm. Because the time window between the
before and after medication activity tasks is very narrow, it is unlikely that physiological
variations during the day or routine habits will bias the effect of the medication. Panel b
shows an example where the participant takes the medication once per day between 10am
and 2pm. In this case the participant is even less prone to confounding effects due to
TOD, since the “before medication” task in one day can be performed later than the “after
medication” task of another day, and vice-versa (note how the red and blue triangles are
intermingled). Panel c illustrates the case where the participant takes the medication, reg-
ularly, but at 7am, noon, and 5pm. As long as the suggestions are also randomized across
these three times of the day, bias due to the TOD will be less of an issue as well.
of time after taking the medication. For instance, if the drug is known to
reach its peak effect in about one hour after intake, then the “after medica-
tion” suggestion should be “please, perform the activity task about one hour
after taking your medication”. In this way, we have that for the participants
that take their medication at the same time everyday, the difference in the
time that the participant performs the before and after medication tasks will
be about one hour only, so that the influence of physiological variations dur-
ing the day will be minimized. Supplementary Figure S10b illustrates this
case, where the narrow time window makes it reasonable to assume that, at
least approximately, there is no influence of Tt on Yt. (Of course, however, if
the participant usually takes medication early in the morning and routinely
performs the “before medication” task using pajamas and sandals, and the
“after medication” task one hour after taking medication, and after having
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changed clothes, the medication effect might still be biased by the “clothing
effect”. However, by keeping a narrow time window between the before and
after medication activity tasks we decrease the likelihood of coming across
biased effects due to routine habits.)
Observe that data from participants that take their medication according
to a more irregular schedule are less prone to confounding effects due to
TOD, since the “before medication” task in one day can be performed later
than the “after medication” task of another day, and vice-versa. Similarly,
participants that take the medication, regularly, but at multiple times per
day, are also less prone to confounding due to TOD, as long as, the sugges-
tions are also randomized across the medication intake events (e.g., “please,
perform the task just before taking medication, at the second time of the day
that you take your medication” or “please, perform the task one hour after
taking medication, at the first time of the day that you take your medica-
tion”). Supplementary Figure S11 shows a few cartoon examples illustrating
these cases.
11. Appendix B: non-parametric identification of the causal ef-
fects of Zt on Xt and of Zt on Yt. Let G represent a dynamic DAG
for which the IV assumptions i to iii described in the main text hold, but
otherwise arbitrary. Note that, in this case, Zt will always be an exogenous
variable in G (i.e., Zt has no parents in G). Let V represent the set of all
variables in G, and A = V \{Yt, Zt}. Observe that the set A includes instru-
mental and response variables over all time points other than t, treatment
and time specific confounders and covariates over all time points, as well as,
ubiquitous confounders and covariates.
Since Zt is an exogenous variable in G, we can factor the joint distribution
of V as,
(14) P (yt, a, zt) = P (yt, a | zt)P (zt) .
Although the conditional joint distribution, P (yt, a | zt), can be further
factorized according to G, we don’t need to specify the factorization explic-
itly when determining the post-intervention distribution for the intervention
do(Zt = z
′), since application of the truncated factorization formula reduces
to removing P (zt), and replacing zt by z
′ in the remaining conditional dis-
tributions, so that,
(15) P
(
yt, a | do(Zt = z′)
)
= P (yt, a | z′) ,
independent of how P (yt, a | z′) can be further factorized. The marginal
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post-intervention distribution is given by,
(16) P
(
yt | do(Zt = z′)
)
=
∑
a
P (yt, a | z′) = P (yt | z′) ,
where the summation over a is simply a notation for all the summations or
integrations over each one of the variables in the set A.
The average causal effect of Zt on Yt is then given by,
ACE(Zt → Yt) = E
(
Yt | do(Zt = 1)
)− E(Yt | do(Zt = 0))(17)
= E
(
Yt | Zt = 1
)−E(Yt | Zt = 0),
where the second equality follows from (16). Assuming stationarity of the
Yt time series we have that a large sample non-parametric estimate of the
expectation E
(
Yt | Zt = z′
)
is given by,
(18)
∑n
t=1 Yt 1 {Zt = z′}∑n
t=1 1 {Zt = z′}
,
so that,
ÂCE(Zt → Yt) =
∑n
t=1 Yt 1 {Zt = 1}∑n
t=1 1 {Zt = 1}
−
∑n
t=1 Yt 1 {Zt = 0}∑n
t=1 1 {Zt = 0}
=
∑n
t=1 YtZt∑n
t=1 Zt
−
∑n
t=1 Yt (1− Zt)∑n
t=1(1− Zt)
=
n−1
∑n
t=1 ZtYt − (n−1
∑n
t=1 Zt)(n
−1∑n
t=1 Yt)
(n−1
∑n
t=1 Zt)(1− n−1
∑n
t=1 Zt)
.(19)
Now, let B = V \ {Xt, Zt}. Then, by a similar rational it follows that,
(20) P
(
xt | do(Zt = z′)
)
=
∑
b
P (xt, b | z′) = P (xt | z′) ,
and
(21) ÂCE(Zt → Xt) = n
−1∑n
t=1 ZtXt − (n−1
∑n
t=1 Zt)(n
−1∑n
t=1Xt)
(n−1
∑n
t=1 Zt)(1− n−1
∑n
t=1 Zt)
.
12. Appendix C: selection bias in the context of mobile health.
In addition to confounding, selection bias is another major obstacle to the
validity of causal inference in clinical studies. Selection bias is hard to de-
tect in observational and experimental settings, and cannot be removed by
randomization (Bareinboim, Tian, and Pearl 2014). It occurs when samples
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are preferentially selected to the data set, and is a consequence of spuri-
ous association between the exposure and outcome variable generated by
conditioning on a collider node (Hernan, Hernandez-Diaz, and Robins 2004;
Bareinboim, Tian, and Pearl 2014). Supplementary Figure S12 shows three
causal DAGs where Xt is not a cause of Yt, but where conditioning on the
collider node St generates a spurious association between the Xt and Yt vari-
ables. The variable St represents a selection variable, where St = 1 indicates
inclusion in the data set, and St = 0 represents exclusion (i.e., the data is
missing). Note that by restricting the analysis to the data recorded in the
data set, we are effectively conditioning the analysis on St = 1, what induces
a spurious association between Xt and Yt. Panel a represents the case where
both exposure and the outcome influence whether or not the data will be
included in the data set. Panel b shows the case where a latent variable, Lt,
influences the exposure, while both outcome and Lt influence the inclusion
in the data set. Panel c represents the case where Lt influences the outcome,
while both exposure and Lt influence the selection to the data set.
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Fig S12. Causal structures giving rise to selection bias. As pointed by Hernan, Hernandez-
Diaz, and Robins (2004), the term selection bias represents several distinct biases, but
the causal structure underlying all these sort of biases is essentially the same, namely,
selection bias arises when we condition on a collider node, St, which is a common effect of
two variables: one of which is either the exposure or a cause of the exposure, and the other
is either the outcome or a cause of the outcome. Panels a, b, and c show three examples
where conditioning in the collider node, St, leads to selection bias. Note that conditioning
on St leads to spurious association between Xt and Yt because it allows information to
flow between the Xt and Yt by opening up paths between these variables. For instance,
conditioning on St opens up the path Xt → St ← Yt in panel a, the path Xt ← Lt → St ←
Yt in panel b, and the path Xt → St ← Lt → Yt in panel c. The double framing around St
indicates that the analysis is conditional on St = 1.
In the context of our motivating example, the Xt variable can easily in-
fluence the selection of the sample into the data set. For instance, suppose
that a participant feels very debilitated before taking medication. In this
case, it is more likely that the participant will be unable to complete the
activity task when unmedicated than when medicated. The Yt variable, on
the other hand, does not seem to be able to influence St. Please recall that
in our application the outcome Yt is simply a quantitative feature extracted
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from the activity task (e.g., number of taps in fixed time interval) and mea-
sures the participant’s performance in the task. (It is very different in nature
than the outcome of, for example, a case-control study, where the outcome
represents an indicator of disease status, and the arrow from the outcome to
the selection variable indicates that cases are more likely to be selected to
the study than non-cases.) Observe, nonetheless, that selection bias can still
play a role in our application in situations where the outcome and selection
variables are both influenced by a common latent variable, as illustrated in
Supplementary Figure S12c.
We point out, however, that informative missing data mechanisms do
not necessarily lead to selection bias. Supplementary Figure S13 shows two
plausible examples that might play a role in our motivating application.
Panel a revisits the case where a participant feels very debilitated before
taking medication, and is more likely to produce missing data when Xt = 0,
than whenXt = 1. In this example, the latent variable Dt corresponds to the
debilitation state of the participant, and shows that the treatment influences
the debilitation state which, by its turn, influences the likelihood that the
participant will be able to perform/complete the task and contribute a data
point (i.e., Xt → Dt → St). Furthermore, it is also likely that the debilitation
status influences the performance of the participant in the activity task (i.e.,
Dt → Yt). Observe, however, that contrary to the DAGs in Supplementary
Figure S12, conditioning on St does not generate further spurious association
between Xt and Yt, since St is not a collider (or a descendent of a collider)
in the DAG in Supplementary Figure S13a. Hence, selection bias will not
be an issue in this example, even though data collection is subjected to an
informative missing data mechanism.
Supplementary Figure S13b shows still another example where an infor-
mative missing data mechanism does not lead to selection bias. Now, suppose
a participant has a very competitive personality and enjoys winning and ex-
celling in any activity that he/she participates. If the participant feels he/she
achieves better performance on the activity task when medicated (Xt = 1),
the participant might be more prone to skip the activity in the days he/she
is assigned to do it before taking medication (Zt = 0), than when assigned to
do it after medication (Zt = 1), generating, in this way, another non-random
missing data pattern. In this example, the selection variable is directly in-
fluenced by the treatment suggestion (i.e., Zt → St), and, once again, St is
not a collider.
Supplementary Figure S14a, on the other hand, shows an example where
an informative missing data/selection mechanism indeed leads to selection
bias. Here, suppose that the latent variable Lt represents the depression level
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Fig S13. Examples, where informative missing data/selection mechanisms do not lead to
selection bias. Because St is not a collider, in both panels, conditioning on St does not
lead to selection bias in these examples.
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Fig S14. Examples of selection bias. Panel a shows an example where an informative miss-
ing data/selection mechanism leads to selection bias. Because St is a collider, conditioning
on St opens an additional path, Xt → Dt → St ← Lt → Yt, between Xt and Yt, biasing
the causal effect of Xt on Yt. Panel b shows an example of selection bias due to selecting
on the treatment. Note that while this type of bias is not an issue in our motivating appli-
cation (since our treatment variable is genuinely binary), selecting on the treatment can be
another important source of bias in other mobile health applications. For example, suppose
that the goal is to compare two distinct medications, but where the participant sometimes
doesn’t take any of the two drugs. In this case the treatment variable has three levels,
namely, “drug A”, “drug B”, and “no drug”. Suppose, as well, that the drugs are equally
effective, so that β = E[Yt | Xt = A]− E[Yt | Xt = B] = 0, and we don’t see an effect of
Xt on the outcome Yt. By restricting the analysis to days where the participant took either
drug A or B, we are effectively conditioning on the collider node Xt, and generating an
spurious association between Zt and Yt, by opening the path Zt → Xt ← Ut → Yt. Conse-
quently, the IV estimator will produce a biased estimate since its numerator, Ĉov(Zt, Yt),
will capture this spurious association.
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of the participant on day t. It is reasonable to expect that a participant
might be more inclined to skip an activity task when depressed than when
feeling well (i.e., Lt → St). Additionally, a participant might achieve better
performance on an activity task when felling well, as opposed to when feeling
depressed (i.e., Lt → Yt). In this example, the informative missing data
mechanism, due to the joint influence of the debilitation and depression
level, will lead to selection bias, since conditioning on the collider St leads
to spurious additional association between Xt and Yt by opening the path
Xt → Dt → St ← Lt → Yt. This selection mechanism induces a bias in
the instrumental variable estimator since its numerator, Cov(Zt, Yt), ends
up capturing association generated by both paths Zt → Xt → Dt → Yt and
Zt → Xt → Dt → St ← Lt → Yt, instead of only by the Zt → Xt → Dt → Yt
path.
Finally, we point out that while selection bias due to selecting on the
treatment (Swanson et al. 2015) is not an issue in our motivating application
(since our treatment variable is genuinely binary), selecting on the treatment
can be another important source of bias in mobile health applications where
the analysis is restricted to two levels of a treatment variable that is not
actually binary, as illustrated in Supplementary Figure S14b.
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